Identification of Rev-erbα as a physiological repressor of apoC-III gene transcription
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Elevated serum levels of triglyceride-rich remnant lipoproteins (TRL) are a major risk factor predisposing a subject to atherosclerosis. Apolipoprotein C-III (apoC-III) is a major constituent of TRL that impedes triglyceride hydrolysis and remnant clearance and, as such, may exert pro-atherogenic activities. In the present study, transient cotransfection experiments in rat hepatocytes in primary culture and rabbit kidney RK13 cells demonstrated that overexpression of Rev-erbalpha specifically decreases basal and HNF-4 stimulated human apoC-III promoter activity. A Rev-erbalpha response element was mapped by promoter deletion, mutation analysis, and gel-shift experiments to a AGGTCA half-site located at position -23/-18 (downstream of the TATA box) in the apoC-III promoter. Finally, Rev-erbalpha-deficient mice displayed elevated serum and liver mRNA levels of apoC-III together with increased serum VLDL triglycerides. Taken together, our data identify Rev-erbalpha as a regulator of apoC-III gene expression, providing a novel, physiological role for this nuclear receptor in the regulation of lipid metabolism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Orphan Nuclear Receptors: From Gene to Function*
Giguère, V. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0378 · Cited by 855
Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3
Jong, M. C., Hofker, M. H., & Havekes, L. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.472 · Cited by 539 · cited 2×
“Although apoC-III plays an important role in intravascular triglyceride metabolism (7, 8), other genes contribute to the control of their synthesis or degradation and thus influence serum triglyceride concentrations.”
BackgroundAlterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice
Peters, J. M., Hennuyer, N., Staels, B., Fruchart, J.-C., Fievet, C., Gonzalez, F. J., & Auwerx, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.43.27307 · Cited by 429 · cited 9×
“Lipoprotein triglyceride profiles were obtained by fast protein liquid chromatography (FPLC) and triglyceride concentration measurement in the eluted fractions as previously described (41).”
BackgroundMethodSelf-citationOrphan Nuclear Receptors: From Gene to Function
Giguère, V. (1999) · Endocrine Reviews · doi:10.1210/er.20.5.689 · Cited by 423 · cited 2×
“The lack of an AF2 transactivation domain in the hRev-erb ligand-binding domain rather suggests that it is unlikely that such ligand exists (23).”
Background[1] Introduction to the plasma lipoproteins
Gotto, A. M., Pownall, H. J., & Havel, R. J. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)28061-1 · Cited by 421 · cited 3×
“jor protein constituent of HDL and apoA-IV, also present in HDL (43), are both involved in reverse cholesterol transport and have a protective impact on atherosclerosis”
BackgroundInfluentialStaels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117717 · Cited by 410 · cited 2×
“ApoC-III gene expression is tightly regulated, being repressed by hormones such as insulin (9, 10) or thyroid hormones (11), cytokines such as interleukin-1 (12) or tumor necrosis factor (13), as well as hypolipidemic drugs such as fibrates (14, 15), or -blocked fatty acids (16, 17).”
BackgroundMethodSelf-citationKarathanasis, S. K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6374 · Cited by 358 · cited 2×
“The apoC-III gene is located on chromosome 11q23 between the apoA-I and apoA-IV genes (19).”
BackgroundMode of Action of Peroxisome Proliferators as Hypolipidemic Drugs.
Hertz, R., Bishara-Shieban, J., & Bar-Tana, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13470 · Cited by 339 · cited 3×
“ApoC-III gene expression is tightly regulated, being repressed by hormones such as insulin (9, 10) or thyroid hormones (11), cytokines such as interleukin-1 (12) or tumor necrosis factor (13), as well as hypolipidemic drugs such as fibrates (14, 15), or -blocked fatty acids (16, 17).”
BackgroundThe Münster Heart Study (PROCAM). Results of follow-up at 8 years.
Assmann, G., Cullen, P., & Schulte, H. (1998) · PubMed · Cited by 332
Cited by
Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β
Cho, H., Zhao, X., Hatori, M., Yu, R. T., Barish, G. D., Lam, M. T., Chong, L.-W., DiTacchio, L., Atkins, A. R., Glass, C. K., et al. (2012) · Nature · doi:10.1038/nature11048 · Cited by 1,037
Peroxisome Proliferator-Activated Receptor Alpha Target Genes
Rakhshandehroo, M., Knoch, B., Müller, M., & Kersten, S. (2010) · PPAR Research · doi:10.1155/2010/612089 · Cited by 1,020
“[217] E.”
BackgroundMolecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
Self-citationTime for food: the intimate interplay between nutrition, metabolism, and the circadian clock
Asher, G., & Sassone-Corsi, P. (2015) · Cell · doi:10.1016/j.cell.2015.03.015 · Cited by 844
Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists
Solt, L. A., Wang, Y., Banerjee, S., Hughes, T., Kojetin, D. J., Lundasen, T., Shin, Y., Liu, J., Cameron, M. D., Noel, R., et al. (2012) · Nature · doi:10.1038/nature11030 · Cited by 831
Metadata
- Authors
- Raspé, E., Duez, H., Mansén, A., Fontaine, C., Fiévet, C., Fruchart, J.-C., Vennström, B., & Staels, B.
- Affiliations
- Inserm (FR)
- Karolinska Institutet (SE)
- Corresponding author
- Staels, Bart
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2002-12
- Volume
- 43
- Issue
- 12
- Pages
- 2172-2179
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W1983841082
- Cited by
- 183
- References
- 51
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 6 · 2023: 5 · 2022: 15 · 2021: 14 · 2020: 12 · 2019: 3 · 2018: 4 · 2017: 9 · 2016: 2 · 2015: 8 · 2014: 11 · 2013: 12 · 2012: 12
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6486 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- NR1D1, apolipoprotein C-III, transcriptional repression, atherosclerosis, HNF4, promoter regulation, VLDL triglycerides, lipid metabolism, hepatocytes
- MeSH terms
- Animals, Apolipoproteins C, DNA-Binding Proteins, Gene Expression Regulation, Humans, Male, Mice, Inbred BALB C, Promoter Regions, Genetic, RNA, Messenger, Transcription, Genetic, Cholesterol, VLDL, Receptors, Cytoplasmic and Nuclear, Hepatocytes, Mice, Rats, Apolipoprotein C-III, Nuclear Receptor Subfamily 1, Group D, Member 1, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of Rev-erbα as a physiological repressor of apoC-III gene transcription. https://app.cochat.ai/papers/10.1194/jlr.m200386-jlr200
- The paper
- Raspé, E., Duez, H., Mansén, A., Fontaine, C., Fiévet, C., Fruchart, J.-C., Vennström, B., & Staels, B. (2002). Identification of Rev-erbα as a physiological repressor of apoC-III gene transcription. Journal of Lipid Research. https://doi.org/10.1194/jlr.m200386-jlr200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.